JP2024502174A - Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用 - Google Patents

Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用 Download PDF

Info

Publication number
JP2024502174A
JP2024502174A JP2023541657A JP2023541657A JP2024502174A JP 2024502174 A JP2024502174 A JP 2024502174A JP 2023541657 A JP2023541657 A JP 2023541657A JP 2023541657 A JP2023541657 A JP 2023541657A JP 2024502174 A JP2024502174 A JP 2024502174A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
alkylene
haloalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502174A5 (https=
Inventor
アル－アワル、リマ
アッティサーノ、リリアーナ
イサーク、メトヴィン
リウ、ヨン
スマイル、デイヴィッド
ユーリン、デイヴィッド
ウラナ、ジェフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of JP2024502174A publication Critical patent/JP2024502174A/ja
Publication of JP2024502174A5 publication Critical patent/JP2024502174A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023541657A 2021-01-07 2022-01-07 Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用 Pending JP2024502174A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134739P 2021-01-07 2021-01-07
US63/134,739 2021-01-07
PCT/CA2022/050014 WO2022147620A1 (en) 2021-01-07 2022-01-07 Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2024502174A true JP2024502174A (ja) 2024-01-17
JP2024502174A5 JP2024502174A5 (https=) 2024-12-10

Family

ID=82356983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541657A Pending JP2024502174A (ja) 2021-01-07 2022-01-07 Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用

Country Status (7)

Country Link
US (1) US20240025887A1 (https=)
EP (1) EP4274829A4 (https=)
JP (1) JP2024502174A (https=)
CN (1) CN116981664A (https=)
AU (1) AU2022205713A1 (https=)
CA (1) CA3204383A1 (https=)
WO (1) WO2022147620A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116903591B (zh) * 2023-07-13 2025-08-26 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN116903592B (zh) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN116947764B9 (zh) * 2023-07-13 2025-07-25 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538092A (ja) * 2004-05-18 2007-12-27 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
JP2009520807A (ja) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
JP2009533378A (ja) * 2006-04-10 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２，４−ジアミノピリミジン誘導体及び癌の治療のためのそれらの使用
JP2010507665A (ja) * 2006-10-23 2010-03-11 セファロン、インク． ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体
JP2010513406A (ja) * 2006-12-22 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療のための細胞周期キナーゼ阻害剤としての２−［（フェニルアミノ）−ピリミジン−４−イルアミノ］−シクロペンタンカルボキサミド誘導体及び関連化合物
JP2010538004A (ja) * 2007-08-28 2010-12-09 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての２−ビフェニルアミノ−４−アミノピリミジン誘導体
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
CN110724137A (zh) * 2019-11-13 2020-01-24 广东工业大学 一种噻吩类衍生物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538092A (ja) * 2004-05-18 2007-12-27 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
JP2009520807A (ja) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
JP2009533378A (ja) * 2006-04-10 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２，４−ジアミノピリミジン誘導体及び癌の治療のためのそれらの使用
JP2010507665A (ja) * 2006-10-23 2010-03-11 セファロン、インク． ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体
JP2010513406A (ja) * 2006-12-22 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療のための細胞周期キナーゼ阻害剤としての２−［（フェニルアミノ）−ピリミジン−４−イルアミノ］−シクロペンタンカルボキサミド誘導体及び関連化合物
JP2010538004A (ja) * 2007-08-28 2010-12-09 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての２−ビフェニルアミノ−４−アミノピリミジン誘導体
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
CN110724137A (zh) * 2019-11-13 2020-01-24 广东工业大学 一种噻吩类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
WO2022147620A1 (en) 2022-07-14
EP4274829A1 (en) 2023-11-15
US20240025887A1 (en) 2024-01-25
CN116981664A (zh) 2023-10-31
AU2022205713A9 (en) 2025-03-06
AU2022205713A1 (en) 2023-07-27
CA3204383A1 (en) 2022-07-14
EP4274829A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
JP2024502175A (ja) Ｎｕａｋキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用
KR101775085B1 (ko) 알파-v-베타-6 인테그린 길항제로서 유용한 나프티리딘 유도체
JP2024502174A (ja) Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用
JP6672276B2 (ja) 新規化合物
EP3433254B1 (en) Naphthyridines as integrin antagonists
JP6321821B2 (ja) ２，３，４，６−４置換ベンゼン−１，５−ジアミン誘導体、その製造方法および医薬品における使用
TWI531573B (zh) 新穎反轉模擬物之化合物及其用途
CA3073977A1 (en) Inhibitors of wdr5 protein-protein binding
JP2017528503A (ja) 新規化合物αｖβ６インテグリンアンタゴニスト
KR20060015283A (ko) 신규한 피리도피라진 및 키나제 억제제로서의 이의 용도
WO2019119138A1 (en) Novel quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
WO2006008874A1 (ja) アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤
RS51912B (sr) DERIVATI 1,2,3,4-TETRAHIDROPIROLO(1,2-a)PIRAZIN-6-KARBOKSAMIDA I 2,3,4,5-TETRAHIDROPIROLO(1,2-a)(1,4)-DIAZEPIN-7-KARBOKSAMIDA NJIHOVO DOBIJANJE I TERAPEUTSKA PRIMENA
CN114502161B (zh) 具有心肌细胞增殖活性的杂环衍生物在治疗心脏病中的用途
EP4313294B1 (en) 3-substituted 1h-pyrrolo[2,3-b]pyridine as grk5 modulators
CA3086362C (en) Quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
HK40119710B (zh) 嘧啶并［6，1-a］异喹啉-4-酮衍生物及其用途
HK40119710A (zh) 嘧啶并[6，1-a]异喹啉-4-酮衍生物及其用途
EP4654966A1 (en) Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
HK40088982A (zh) Lpa受体拮抗剂及其用途
HK40088982B (zh) Lpa受体拮抗剂及其用途
JP5846527B2 (ja) ＴＧＦ−βシグナル伝達阻害剤
HK40115315A (zh) Lpa受体拮抗剂及其用途
CN118184572A (zh) 一类新型HsClpP激动剂的制备及其在抗炎抗肿瘤中的用途
HK40105333A (zh) Lpa受体拮抗剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303